

Resource Summary Report

Generated by [RRID](#) on Jul 30, 2026

NCI-ADR-RES

RRID:CVCL_1452

Type: Cell Line

Proper Citation

RRID:CVCL_1452

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1452

Proper Citation: RRID:CVCL_1452

Description: Cell line NCI-ADR-RES is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: High grade ovarian serous adenocarcinoma

Defining Citation: [PMID:9331090](#), [PMID:9625176](#), [PMID:10700174](#), [PMID:11416159](#), [PMID:15748285](#), [PMID:16504380](#), [PMID:17088437](#), [PMID:18304946](#), [PMID:19372543](#), [PMID:20143388](#), [PMID:21116879](#), [PMID:22068913](#), [PMID:22347499](#), [PMID:22384151](#), [PMID:22628656](#), [PMID:23933261](#), [PMID:24279929](#), [PMID:24670534](#), [PMID:27377824](#), [PMID:27807467](#), [PMID:31733513](#), [PMID:38861359](#)

Comments: Population: Caucasian., Part of: NCI-60 cancer cell line panel., Problematic cell line: Contaminated. Shown to be a OVCAR-8 derivative (PubMed=16504380; PubMed=18304946; PubMed=20143388). Originally thought to be a derivative of MCF-7..

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NCI-ADR-RES

Synonyms: NCI/ADR-RES, NCI.ADR.RES, NCIADR.RES, NCI/ADRRES, NCIADRRES, ADR-RES, MCF-7/ADR, MCF-7/ADR-RES, MCF-7/AdrR, MCF-7/Adr, MCF-7/adr, MCF-7ADR, MCF7-ADR, MCF7ADR, OVCAR-8/ADR, OVCAR8/ADR

Cross References: BTO:BTO_0004181, MCCL:MCC:0000310, ArrayExpress:E-MTAB-783, BioGRID_ORCS_Cell_line:390, BioSample:SAMN03151880, BioSample:SAMN03151881, cancercellines:CVCL_1452, CancerTools:161022,

Cell_Model_Passport:SIDM00089, ChEMBL-Cells:CHEMBL3308057, ChEMBL-Targets:CHEMBL613829, Cosmic:687498, Cosmic:897420, Cosmic:905987, Cosmic:974233, Cosmic:1044218, Cosmic:1092617, Cosmic:1312358, Cosmic:1998459, GEO:GSM2099, GEO:GSM50197, GEO:GSM50260, GEO:GSM743473, GEO:GSM750832, GEO:GSM799367, GEO:GSM799430, GEO:GSM839041, GEO:GSM844614, GEO:GSM844615, GEO:GSM847073, GEO:GSM1153433, GEO:GSM1181271, GEO:GSM1181300, GEO:GSM2124672, IARC_TP53:21533, NCI-DTP:NCI/ADRRES, PRIDE:PXD003539, PRIDE:PXD005942, PRIDE:PXD005946, Progenetix:CVCL_1452, PubChem_Cell_line:CVCL_1452, SKY/M-FISH/CGH:2897, Wikidata:Q54907717

ID: CVCL_1452

Hierarchy: cvcl_1629

Record Creation Time: 20220427T220836+0000

Record Last Update: 20260725T235040+0000

Ratings and Alerts

No rating or validation information has been found for NCI-ADR-RES.

Warning: Problematic cell line: Contaminated. Shown to be a OVCAR-8 derivative (PubMed=16504380; PubMed=18304946; PubMed=20143388). Originally thought to be a derivative of MCF-7.

Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00234.

Population: Caucasian., Part of: NCI-60 cancer cell line panel., Problematic cell line: Contaminated. Shown to be a OVCAR-8 derivative (PubMed=16504380; PubMed=18304946; PubMed=20143388). Originally thought to be a derivative of MCF-7..

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 361 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Kunkel MW, et al. (2024) HTS384 NCI60: The Next Phase of the NCI60 Screen. Cancer research, 84(15), 2403.

Bischof K, et al. (2024) Patient-derived acellular ascites fluid affects drug responses in ovarian cancer cell lines through the activation of key signalling pathways. Molecular oncology.

Kim CH, et al. (2023) Functionalized Lipid Nanocarriers for Simultaneous Delivery of Docetaxel and Tariquidar to Chemoresistant Cancer Cells. *Pharmaceuticals* (Basel, Switzerland), 16(3).

Peng H, et al. (2023) Defect self-assembly of metal-organic framework triggers ferroptosis to overcome resistance. *Bioactive materials*, 19, 1.

Zhang T, et al. (2023) Enhanced therapeutic efficacy of doxorubicin against multidrug-resistant breast cancer with reduced cardiotoxicity. *Drug delivery*, 30(1), 2189118.

Zhao S, et al. (2023) Design, synthesis and anti-breast cancer properties of butyric ester tethered dihydroartemisinin-isatin hybrids. *Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents*, 32(4), 705.

Wang R, et al. (2023) Tumor microenvironment-responsive micelles assembled from a prodrug of mitoxantrone and 1-methyl tryptophan for enhanced chemo-immunotherapy. *Drug delivery*, 30(1), 2182254.

Jian FX, et al. (2023) Negative regulation of CD44st by miR-138-5p affects the invasive ability of breast cancer cells and patient prognosis after breast cancer surgery. *BMC cancer*, 23(1), 269.

Han E, et al. (2023) Development of Polymersomes Co-Delivering Doxorubicin and Melittin to Overcome Multidrug Resistance. *Molecules* (Basel, Switzerland), 28(3).

Mukhtar MH, et al. (2023) Cymbopogon citratus and Citral Overcome Doxorubicin Resistance in Cancer Cells via Modulating the Drug's Metabolism, Toxicity, and Multidrug Transporters. *Molecules* (Basel, Switzerland), 28(8).

Pan M, et al. (2023) Poly(l-Ornithine)-Based Polymeric Micelles as pH-Responsive Macromolecular Anticancer Agents. *Pharmaceutics*, 15(4).

Wang C, et al. (2023) Design, Synthesis, and Biological Evaluation of Marine Lissodendrins B Analogues as Modulators of ABCB1-Mediated Multidrug Resistance. *Marine drugs*, 21(5).

Shao W, et al. (2023) Cyperotundone combined with adriamycin induces apoptosis in MCF-7 and MCF-7/ADR cancer cells by ROS generation and NRF2/ARE signaling pathway. *Scientific reports*, 13(1), 1384.

Li Y, et al. (2023) Ethane groups modified DNA nanopores to prolong the dwell time on live cell membranes for transmembrane transport. *Frontiers in chemistry*, 11, 1148699.

Miri A, et al. (2023) Identification of co-regulated genes associated with doxorubicin resistance in the MCF-7/ADR cancer cell line. *Frontiers in oncology*, 13, 1135836.

Abdelaziz MH, et al. (2023) A Novel Electrochemical Differentiation between Exosomal-RNA of Breast Cancer MCF7 and MCF7/ADR-Resistant Cells. *Pharmaceuticals* (Basel, Switzerland), 16(4).

Chen Z, et al. (2023) Hypoxia-ameliorated photothermal manganese dioxide nanoplatfrom for reversing doxorubicin resistance. *Frontiers in pharmacology*, 14, 1133011.

Dong H, et al. (2023) YB-1 Expression Is Associated with Lymph Node Metastasis and Drug Resistance to Adriamycin in Breast Cancer. *Disease markers*, 2023, 4667089.

Han X, et al. (2023) miR-1275 targets MDK/AKT signaling to inhibit breast cancer chemoresistance by lessening the properties of cancer stem cells. *International journal of biological sciences*, 19(1), 89.

Ju R, et al. (2023) Dual Sensitization Anti-Resistant Nanoparticles for Treating Refractory Breast Cancers via Apoptosis-Inducing. *Drug design, development and therapy*, 17, 403.